Peptide-Drug Conjugates for Cancer: Smaller, Deeper-Penetrating Alternatives to Antibody-Drug Conjugates

PDCs are small (~1-3 kDa) targeted therapeutics that use homing peptides to deliver cytotoxic drugs to tumors, offering superior tissue penetration and faster clearance compared to antibody-drug conjugates (ADCs, ~150 kDa). Currently, only one PDC is FDA-approved: lutetium (177Lu)-DOTATATE (Lutathera) for neuroendocrine tumors. Other PDCs in development include paclitaxel-Angiopep-2 (ANG1005) for brain tumors and LyP-1-doxorubicin conjugates for triple-negative breast cancer. Key challenges remain: premature drug release, metabolic clearance, variable receptor expression across tumors, and manufacturing scale-up. Melflufen, another PDC, faced clinical setbacks.

Comprehensive narrative review covering PDC design principles (targeting peptides, linker chemistry, drug payloads), mechanisms of tumor delivery and drug release, specific clinical examples, comparison with ADCs, current challenges, and future directions including AI-assisted design and theranostic applications.

Antibody-drug conjugates (ADCs) are already a multi-billion-dollar cancer drug class, but their large size limits how deeply they penetrate tumors. PDCs are essentially the smaller, nimbler cousin — they can reach parts of tumors that antibodies can't and are cheaper to manufacture. With only one FDA-approved PDC so far, the field is still early but has enormous potential, especially with AI-assisted design and theranostic (imaging + therapy) approaches emerging.

ADCs like trastuzumab emtansine (Kadcyla) and enfortumab vedotin (Padcev) have become blockbuster cancer drugs, validating the concept of targeted drug delivery. PDCs represent the next evolution — achieving similar targeting with dramatically smaller, cheaper molecules. The review arrives at an inflection point: AI-assisted peptide design could dramatically accelerate PDC discovery, and theranostic PDCs (combining imaging and therapy in one molecule, like Lutathera) represent a paradigm shift in personalized cancer treatment. However, the field must overcome the disconnect between promising preclinical data and limited clinical success.

This is a review article, not an experimental study. The field faces significant practical challenges: only one PDC has achieved FDA approval while others (like melflufen) have failed or stalled. The advantages of PDCs over ADCs (better penetration, cheaper manufacturing) must be weighed against disadvantages (faster clearance means shorter drug exposure, potentially requiring more frequent dosing).